CapsoVision, Inc. (CV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.99+0.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 342.0% |
| Our one-year growth estimate | diamond | 28.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 313.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CV — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release, dated August 13, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor sha…
Why it matters: This partnership could improve products and help in the market.
Supportive ifA press release shares news about products from the Canon partnership.
Worry ifNo news or bad updates about the Canon partnership.
Why it matters: Getting this money is important for operations and growth.
Supportive ifAn announcement says the $14M private placement is done.
Worry ifFailure to secure the $14M in funding or delays in the placement process.
Why it matters: FDA clearance would enable commercial launch, boosting adoption of CapsoCam Plus. This could enhance workflow for physicians.
Supportive ifFDA grants clearance for the AI-assisted reading feature for CapsoCam Plus.
Worry ifFDA delays or denies clearance for the AI-assisted reading feature.
Why it matters: This submission helps CapsoVision move forward with its products and market presence.
Supportive if510(k) submission completed in Q4 2026.
Worry ifSubmission postponed beyond Q4 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$198 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $985 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,782 loss on $10,000 · 67.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Steady revenue growth shows strong demand and good sales plans.
Supportive ifQ3 2026 revenue growth of at least 10% year over year.
Worry ifQ3 2026 revenue growth below 5% year over year.
Why it matters: More people using the product means it is accepted and can earn more money.
Supportive ifCapsoCam Plus used by over 180,000 patients by Q4 2026.
Worry ifIf CapsoCam Plus use stops growing or falls.
Why it matters: FDA clearance would enable the U.S. launch of AI Highlights, boosting sales and adoption.
Supportive ifFDA clearance granted by the end of Q3 2026.
Worry ifFDA clearance delayed beyond Q3 2026.
Why it matters: If revenue growth speeds up, it may show good news for CapsoVision.
Supportive ifSector revenue growth moves back toward 10% or higher.
Worry ifSector revenue growth continues to decline or stays below 10%.
Why it matters: This product is key for CapsoVision's future. Delays could hurt growth plans.
Supportive ifA public update shows big progress or a successful trial for CapsoCam Colon.
Worry ifThere are no updates. CapsoCam Colon development faces more delays.
Why it matters: Getting new customers is key for growing market share and proving product value.
Supportive ifCapsoVision announces new contracts with at least two large GI networks by the end of Q4 2026.
Worry ifNo new large GI network contracts are announced by the end of Q4 2026.
Why it matters: Progress in this study could prove CapsoVision's technology. It may also widen its market.
Supportive ifThe first results or updates from the pancreatic cancer study are released.
Worry ifNo updates or bad results from the clinical study are reported.